The Humatrope dosage and administration schedule should be individualized for each patient. Therapy should not be continued if epiphyseal fusion has occurred. Response to growth hormone therapy tends to decrease with time. However, failure to increase growth rate, particularly during the first year of therapy, should prompt close assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism, under-nutrition and advanced bone age. Growth hormone-deficient pediatric patients – The recommended weekly dosage is 0.18 mg/kg (0.54 IU/kg) of body weight. The maximal replacement weekly dosage is 0.3 mg/kg (0.90 IU/kg) of body weight. It should be divided into equal doses given either on three alternate days, six times per week or daily. The intravenous route of administration is the preferred method. The dosage and administration schedule for Humatrope should be individualized for each patient. Turner Syndrome – A weekly dosage of up to 0.375 mg/kg (1.125 IU/kg) of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given either daily or on 3 alternate days. Patients with idiopathic short stature – A weekly dosage of up to 0.37 mg/kg of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given 6 to 7 times per week.
Growth hormone-deficient adult patients – The recommended dosage at the start of therapy is not more than 0.006 mg/kg/day (0.018 IU/kg/day) given as a daily subcutaneous injection. The dose may be increased according to individual patient requirements to a maximum of 0.0125 mg/kg/day (0.0375 IU/kg/day).
About Eli Lily
Founded in 1876 by Colonel Eli Lily is a globe spanning research and pharmaceutical firm with it’s headquarters in Indianapolis, Indiana. The firm did North of $24 billion in revenue in 2011 and spends $5 billion dollars a year in research alone. The company has 38,000 employees and manufacturing plants in 13 countries.